IP Library Granted Patent US 9,115,342
Granted Patent B2
US 9,115,342 · App. 12/162,684 · Granted Aug 25, 2015

Method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,115,342
App. No.
12/162,684
Granted
Aug 25, 2015
Kind
B2
Abstract

An object of the present invention is to develop a method for purify cardiomyocytes at a high degree of purification and at a high yield from a cell mixture comprising cardiomyocytes derived from fetuses and stem cells using various features which have not been previously expected to be used for purification of cardiomyocytes or which are newly found, wherein said method is carried out without undergoing any genetic modification or without adding any special proteins or biologically active agents.

Claims (27)

1. A method of selecting cardiomyocytes and/or Brachyury+/Nkx2.5-cells capable of differentiating into cardiomyocytes from a cell mixture containing cardiomyocytes, Brachyury+/Nkx2.5-cells, and non-cardiomyocyte cells comprising:

Culturing the cell mixture in a culture medium under the following conditions:

(i) a sugar-free condition or a condition wherein sugar content is 111.20 μM or less; and

(ii) one or more conditions selected from the group consisting of a low calcium condition, a low nutritional condition, a lactic acid-supplemented condition, an aspartic acid/glutamic acid-supplemented condition, and a pyruvic acid-supplemented condition to select the cardiomyocytes and/or Brachyury+/Nkx2.5-cells from the cell mixture, wherein the cell mixture is derived from totipotent cells, pluripotent cells, or stem cell having similar characteristics to those of embryonic stem cell through differentiation induction, wherein the low nutritional condition is a condition where the content of each nutritional component of the cultured medium is reduced to 10% or less of that of a culture medium selected from the group consisting of RPMI culture medium, DMEM culture medium, MEM culture medium, F12 culture medium, and α-MEM culture medium, and wherein the stem cells having similar characteristics to those of embryonic stem cells have surface markers specific for embryonic stem cells, have embryonic stem cell specific gene expression, and/or have an ability to form a teratoma.

2. The method of claim 1 , further comprising eliminating dead cells adhered to the cardiomyocytes and/or the Brachyury+/Nkx 2 . 5 -cells by treating the cell mixture with a collagenase.

3. The method of claim 2 , wherein the dead cells are eliminated based on the filet that the specific gravity of the dead cells is higher than that of the cardiomyocytes and/or the Brachyury+/Nkx2.5-cells.

4. The method of claim 1 , wherein the condition (ii) of the culture medium is a lactic acid-supplemented condition.

5. The method claim 1 , wherein the condition (ii) of the culture medium is an aspartic acid/glutamic acid-supplemented condition.

6. The method of claim 1 , wherein the condition (ii) of the culture medium is a pyruvic acid-supplemented condition.

7. The method of claim 1 , wherein the cell mixture is prepared by the following steps of:

inducing differentiation of embryonic stem cells or stem cells having similar characteristics to those of embryonic stem cells in a culture medium;

forming embryoid bodies comprising the Brachyury+/Nkx2.5-cells; and

preparing the cell mixture by culturing the embryoid bodies under a low-serum -supplemented condition and/or a mildly-acidic pH condition, wherein the low-serum -supplemented condition is serum-free condition, or a condition wherein the concentration of serum or serum components is reduced to less than 10% of serum or serum components supplemented to the culture medium used in the step of inducing differentiation.

8. A method for selecting cardiomyocytes and/or Brachyury+/Nkx2.5-cells capable of differentiating into cardiomyocytes derived from embryonic stem cells comprising:

inducing differentiation of embryonic stem cells in a first culture medium to form embryoid bodies comprising the Brachyury+/Nkx2.5-cells;

then preparing a cell mixture comprising the Brachyury+/Nkx2.5-cells by culturing the embryoid bodies in a second culture medium under a low-serum-supplemented condition and a mildly acidic pH condition, wherein the low-serum-supplemented condition is serum-free condition, or a condition wherein the concentration of serum or serum components is reduced to less than 10% of serum or serum components supplemented to the first culture medium used in the process for obtaining the embryoid bodies; and

continuing the culture of the cell mixture in the same culture medium to obtain the cardiomyocytes and/or the Brachyury+/Nkx2.5-cells.

9. The method of claim 1 , wherein the low calcium condition is a condition wherein the calcium concentration in the culture medium ranges between 0.3-1.3 mM.

10. The method of claim 1 , wherein the lactic acid -supplemented condition is a condition wherein 0.1-5 mM of lactic acid is supplemented to the culture medium.

11. The method of claim 1 , wherein the aspartic acid/glutamic acid-supplemented condition is a condition wherein 20-100 mg/L of aspartic acid and 20-100 mg/L of glutamic acid are supplemented to the culture medium.

12. The method of claim 1 , wherein the pyruvic acid -supplemented condition is a condition wherein 0.5-5 mM of pyruvic acid is supplemented to the culture medium.

13. The method of claim 7 , wherein the mildly-acidic pH condition is a condition of pH 6.5.

14. The method of claim 1 , wherein the sugar is glucose.

15. The method of claim 1 , wherein the stem cells having similar characteristics to those of embryonic stem cells are embryonic germ cells (EG cells) produced from primordial germ cells, germline stem cells (GS cells) produced from testicular germ cells, or induced pluripotent stem cells (iPS cells) produced from somatic cells.

16. The method of claim 15 , wherein the stem cells having similar characteristics to those of embryonic stem cells are induced pluripotent stem cells (iPS cells).

17. The method of claim 7 , wherein the concentration of serum or serum components is 0 to 1% in the low-serum-supplemented condition.

18. The method of claim 8 , wherein the concentration of serum or serum components is 0 to 1% in the low-serum-supplemented condition.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 041957 FRAME: 0831. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 10, 2017
From: KEIO UNIVERSITY
To: HEARTSEED INC.
Reel/Frame 042437/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2017
From: KEIO UNIVERSITY
To: HEARTSEED, INC.
Reel/Frame 041957/0831 →
MERGER Recorded Jul 13, 2010
From: ASUBIO PHARMA CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 024673/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2009
From: HATTORI, FUMIYUKI; FUKUDA, KEIICHI
To: ASUBIO PHARMA CO., LTD; KEIO UNIVERSITY
Reel/Frame 022219/0033 →